In the past, advanced breast cancer with positive Human Epidermal growth factor Receptor 2 (HER2+) resulted in a poor prognosis; however, outcomes have since changed after the introduction of HER2-targeting therapy. Here, ERBB2 is linked to breast carcinoma.